Abbott has reported positive data from a randomised clinical trial of its FreeStyle Libre 2 glucose monitoring system.
Published in The New England Journal of Medicine, the study evaluated the efficacy of the FreeStyle Libre 2 system in adult patients with Type 1 diabetes and sub-optimal glycaemic control.
The findings from the study demonstrated that Abbott’s glucose monitoring system provided a significant reduction in glycated hemoglobin (HbA1c) compared to self-monitoring of blood glucose (SMBG).
In the clinical trial, the participants sustained HbA1c reductions for the duration of the 24 week study.
Additionally, the FreeStyle Libre 2 system improved participant-reported quality of life outcomes, including overall satisfaction and reduction in burden related to glucose monitoring.
The average HbA1c levels of participants who used the FreeStyle Libre 2 system were 0.8% less after six months.
Abbott Diabetes Care Business chief medical officer Dr Mahmood Kazemi said: “This randomised study clearly illustrates the importance of continuous glucose monitoring for adults with Type 1 diabetes.
“This clinically-significant change in HbA1c levels shows FreeStyle Libre technology empowers people to make lifestyle decisions that improve their glucose control and, ultimately, may result in a reduction in diabetes-related health problems down the line.”
The study enrolled 156 people aged 16 years and above with Type 1 diabetes that were not previously familiar with continuous glucose sensing technology.
It was conducted as part of FLASH-UK, the first randomised study of the FreeStyle Libre 2 system in comparison to SMBG.
The clinical trial was funded by Diabetes UK and conducted by a team at The University of Manchester with support from investigators at eight centres around the UK.
Related Companies
